BioCryst Pharmaceuticals (BCRX) Analyst & Key Data

Analyst Consensus

Buy9 analysts

Buy

Updated Sep 12, 2026

Total Analysts9

Buy

24

Hold

5

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$8.12

Median Target+95.69%

$15.89

Potential upside vs current price

Current Stock Price

$8.12

Median Target+95.69%

$15.89

Potential upside vs current price

Analyst Consensus

Buy9 analysts

Buy

Updated Sep 12, 2026

Total Analysts9

Buy

24

Hold

5

Ratings

Updated Sep 12, 2026

Overall Rating

B-

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score5.0 / 5

Valuation

Current Stock Price

$8.12

Median Target+95.69%

$15.89

Potential upside vs current price

Current Stock Price

$8.12

Median Target+95.69%

$15.89

Potential upside vs current price

BioCryst Pharmaceuticals, Inc.